Dr Jennifer King has over 20 years of operating experience in the biopharmaceutical industry.
She is a principal of King BioConsulting which provides business development and strategic support for biotechnology companies and other key stakeholders, with a focus on cutting edge technologies and orphan indications.
From 2015 to 2019 Dr King was with Intellia Therapeutics, a CRISPR Cas9 genome editing startup, as senior vice president for business development. She founded and grew its business development and new product commercialization groups; and was responsible for accessing external sources of innovation, establishing the company’s key industry partnerships, overseeing the alliance management activities for these partnerships, and developing commercial strategies and frameworks for the company’s genome editing platform. Prior to Intellia, Dr King was the global brand director and senior director of business development at Shire (now Takeda), and held a variety of commercial roles in at Millennium Pharmaceuticals including as product manager for the US launch of VELCADE®.
Dr King holds a Bachelor of Science in Biology from the Massachusetts Institute of Technology, a PhD in Developmental Biology at the Stanford University School of Medicine, and an MBA from Northeastern University.
